FDA Approves COVID-19 Antibody Treatment

FDA Approves COVID-19 Antibody Treatment

The antibody treatment is approved for administration in hospitals and other health care facilities.

The FDA issued an emergency use authorization for Eli Lilly and Co.’s antibody therapy for coronavirus on November 9, according to CNN.

The pharmaceutical company’s single antibody treatment is the first monoclonal antibody that has been authorized to treat COVID-19. The antibody, which is called bamlanivimab, will be used to initiate an immune response against the virus.

Bamlanivimab is an antibody that is directed against the spike protein of SARS-CoV-2. The FDA authorized the treatment after a New England Journal of Medicine study found that it lowered the risk of hospitalization when used on patients with mild to moderate coronavirus cases.

“The FDA’s emergency authorization of bamlanivimab provides health care professionals on the frontline of this pandemic with another potential tool in treating COVID-19 patients,” said Dr. Patricia Cavazzoni, acting director of the FDA’s Center for Drug Evaluation and Research. “We will continue to evaluate new data on the safety and efficacy of bamlanivimab as they become available.”

Eli Lilly and Co. will ship the antibody treatment to a national distributor so that it can be distributed according to state’s allocation plans. More information can be found at fda.gov.

About the Author

Nikki Johnson-Bolden is an Associate Content Editor for Occupational Health & Safety.

Download Center

HTML - No Current Item Deck
  • Green Quadrant EHS Software 2021

    Reserve your copy of the new report by independent analyst firm, Verdantix, to get a detailed, fact-based comparison of the 22 most prominent EHS software vendors in the industry.

  • Best Practices to Navigate ISO 45001

    Learn helpful tips and tricks to navigate your transition to ISO 45001 certification and ensure an effective health and safety management system.

  • Improve Your Safety Culture

    Learn the 3 fundamental areas to focus on to achieve safety culture excellence and what you can do to boost employee engagement in your EHS programs.

  • Chemical Safety: 5 Questions Answered by Experts

    Get answers to 5 of the most frequently asked questions about how to effectively mitigate chemical risk, get the most value out of your chemical data, and gain buy-in for a chemical management technology program.

  • How Has COVID-19 Changed Safety Culture?

    The COVID-19 pandemic has provided unique opportunities for health and safety professionals to rethink how they manage risk and develop stronger safety cultures. Read this eBook to learn actionable steps you can implement today to improve your programs.

  • Industry Safe

OH&S Digital Edition

  • OHS Magazine Digital Edition - January February 2021

    January February 2021

    Featuring:

    • TRAINING: SOFTWARE
      Tips for Choosing the Best Training Software
    • COMBUSTIBLE DUST
      Assessing the Dangers of Dust Explosions
    • HAND PROTECTION
      Pushing the Boundaries of Hand Protection
    • FOOT PROTECTION
      Getting a Grip on Slip Resistance
    View This Issue